These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 696204)

  • 1. Elimination of paracetamol in chronic liver disease.
    Arnman R; Olsson R
    Acta Hepatogastroenterol (Stuttg); 1978 Aug; 25(4):283-6. PubMed ID: 696204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetaminophen plasma level after oral administration in liver cirrhotic patients suffering from schistosomal infection.
    el-Azab G; Youssef MK; Higashi Y; Murakami T; Yata N
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):299-303. PubMed ID: 8832306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered kinetics of etozolin and its active metabolite ozolinone in hepatitis and hepatic cirrhosis with ascites.
    Knauf H; Missmahl M; Schölmerich J; Gerok W; Mutschler E
    Arzneimittelforschung; 1987 Dec; 37(12):1385-8. PubMed ID: 3449068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic value of the study of caffeine elimination in chronic liver diseases].
    Darnót G; Nemesánszky E; Bariska J
    Orv Hetil; 1995 Apr; 136(18):927-32. PubMed ID: 7739851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis.
    Tonsuwannont W; Praisontarangkul OA; Manorot M; Klangwarnwong D
    J Med Assoc Thai; 1996 May; 79(5):309-19. PubMed ID: 8708523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum laminin in chronic alcoholic liver disease: its value in the estimation of the degree of fibrosis].
    González Reimers E; Santolaria Fernández F; Rodríguez Rodríguez E; Rodríguez Moreno F; Milena Abril A; Martínez-Riera A; García-Castro C
    Rev Esp Enferm Dig; 1996 Apr; 88(4):241-5. PubMed ID: 9004793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxmetidine (SK&F 92994): pharmacokinetic study in patients with in patients with liver cirrhosis.
    Miglio F; Baraldini M; Serra S; Facchini A; Stefanini GF; Meliconi R; Gasbarrini G; Labo' G
    Int J Clin Pharmacol Res; 1985; 5(6):399-404. PubMed ID: 2869000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic liver disease in Ethiopia: a clinical study with emphasis on identifying common causes.
    Tsega E; Nordenfelt E; Hansson BG; Mengesha B; Lindberg J
    Ethiop Med J; 1992 Apr; 30(2 Suppl):1-33. PubMed ID: 1319901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temazepam clearance unaltered in cirrhosis.
    Ochs HR; Greenblatt DJ; Verburg-Ochs B; Matlis R
    Am J Gastroenterol; 1986 Jan; 81(1):80-4. PubMed ID: 2867675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites.
    Alam I; Bass NM; Bacchetti P; Gee L; Rockey DC
    Am J Gastroenterol; 2000 Jan; 95(1):199-203. PubMed ID: 10638583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
    Hayes PC; Bouchier IA
    Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperlactataemia and metabolic acidosis following paracetamol overdose.
    Gray TA; Buckley BM; Vale JA
    Q J Med; 1987 Oct; 65(246):811-21. PubMed ID: 3449887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis].
    Reinicke A; Müller P; Dammann HG; Simon B
    Arzneimittelforschung; 1990 Nov; 40(11):1239-41. PubMed ID: 2085337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Compared alteration in paracetamol and hexobarbital metabolism due to liver disease].
    Brazier JL; Ritter J; Latour JF; Enoch F; Khenfer D; Faucon G
    Therapie; 1982; 37(3):275-80. PubMed ID: 7135308
    [No Abstract]   [Full Text] [Related]  

  • 16. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT; Marigold JH; Thompson RP
    Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver.
    Andreasen PB; Hutters L
    Acta Med Scand Suppl; 1979; 624():99-105. PubMed ID: 284720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status.
    Zapater P; Lasso de la Vega MC; Horga JF; Such J; Frances R; Esteban A; Palazòn JM; Carnicer F; Pascual S; Pérez-Mateo M
    Aliment Pharmacol Ther; 2004 Jul; 20(1):29-36. PubMed ID: 15225168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circadian bioavailability and some effects of propranolol in healthy subjects and in liver cirrhosis.
    Semenowicz-Siuda K; Markiewicz A; Korczyńska-Wardecka J
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):653-8. PubMed ID: 6526540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.